Vera Therapeutics, Inc. Net Income
Vera Therapeutics, Inc. (VERA) reported Net Income of -$109.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-10
- Vera Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$109.47M.
- Vera Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$121.03M.
- Vera Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$91.10M.
- Vera Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$80.29M.
- Vera Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$89.06M.
- Vera Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2021 was -$32.61M.
- Vera Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2020 was -$53.41M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$109.47M 10-Q · filed 2026-08-10 | -$230.50M 10-Q · filed 2026-08-10 | -$321.60M derived: sum of 3 quarters · filed 2026-08-10 | -$401.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$121.03M 10-Q · filed 2026-08-10 | -$212.13M derived: sum of 2 quarters · filed 2026-08-10 | -$292.42M derived: sum of 3 quarters · filed 2026-08-10 | -$368.95M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$91.10M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-09 | -$171.39M derived: sum of 2 quarters · filed 2026-04-09 | -$247.92M derived: sum of 3 quarters · filed 2026-08-10 | -$299.62M DEF 14A · filed 2026-04-09 |
| 2025-09-30 | -$80.29M 10-Q · filed 2025-11-05 | -$156.82M derived: sum of 2 quarters · filed 2026-08-10 | -$208.52M 10-Q · filed 2025-11-05 | -$251.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$76.53M 10-Q · filed 2026-08-10 | -$128.22M 10-Q · filed 2026-08-10 | -$171.65M derived: sum of 3 quarters · filed 2026-08-10 | -$218.28M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$51.69M 10-Q · filed 2026-08-10 | -$95.12M derived: sum of 2 quarters · filed 2026-08-10 | -$141.75M derived: sum of 3 quarters · filed 2026-08-10 | -$175.46M derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | -$43.42M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-09 | -$90.06M derived: sum of 2 quarters · filed 2026-04-09 | -$123.77M derived: sum of 3 quarters · filed 2026-04-09 | -$152.15M DEF 14A · filed 2026-04-09 |
| 2024-09-30 | -$46.63M 10-Q · filed 2025-11-05 | -$80.34M derived: sum of 2 quarters · filed 2025-11-05 | -$108.72M 10-Q · filed 2025-11-05 | -$134.38M derived: sum of 4 quarters · filed 2026-04-09 |
| 2024-06-30 | -$33.71M 10-Q · filed 2025-11-05 | -$62.09M 10-Q · filed 2025-08-05 | -$87.75M derived: sum of 3 quarters · filed 2026-04-09 | -$107.85M derived: sum of 4 quarters · filed 2026-04-09 |
| 2024-03-31 | -$28.38M 10-Q · filed 2025-11-05 | -$54.04M derived: sum of 2 quarters · filed 2026-04-09 | -$74.14M derived: sum of 3 quarters · filed 2026-04-09 | -$94.30M derived: sum of 4 quarters · filed 2026-04-09 |
| 2023-12-31 | -$25.66M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-09 | -$45.76M derived: sum of 2 quarters · filed 2026-04-09 | -$65.92M derived: sum of 3 quarters · filed 2026-04-09 | -$95.99M DEF 14A · filed 2026-04-09 |
| 2023-09-30 | -$20.10M 10-Q · filed 2024-11-07 | -$40.27M derived: sum of 2 quarters · filed 2024-11-07 | -$70.33M 10-Q · filed 2024-11-07 | -$102.77M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$20.16M 10-Q · filed 2024-11-07 | -$50.23M 10-Q · filed 2024-08-08 | -$82.67M derived: sum of 3 quarters · filed 2024-11-07 | -$107.35M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | -$30.07M 10-Q · filed 2024-11-07 | -$62.51M derived: sum of 2 quarters · filed 2024-11-07 | -$87.19M derived: sum of 3 quarters · filed 2024-11-07 | -$102.04M derived: sum of 4 quarters · filed 2024-11-07 |
| 2022-12-31 | -$32.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$57.12M derived: sum of 2 quarters · filed 2024-03-27 | -$71.97M derived: sum of 3 quarters · filed 2024-03-27 | -$89.06M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$24.68M 10-Q · filed 2023-11-09 | -$39.53M derived: sum of 2 quarters · filed 2023-11-09 | -$56.62M 10-Q · filed 2023-11-09 | -$73.46M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$14.85M 10-Q · filed 2023-11-09 | -$31.94M 10-Q · filed 2023-08-10 | -$48.78M derived: sum of 3 quarters · filed 2023-11-09 | -$56.40M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-03-31 | -$17.09M 10-Q · filed 2023-11-09 | -$33.93M derived: sum of 2 quarters · filed 2023-11-09 | -$41.54M derived: sum of 3 quarters · filed 2023-11-09 | -$44.98M derived: sum of 4 quarters · filed 2023-11-09 |
| 2021-12-31 | -$16.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$24.46M derived: sum of 2 quarters · filed 2023-03-28 | -$27.89M derived: sum of 3 quarters · filed 2023-03-28 | -$32.61M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$7.61M 10-Q · filed 2022-11-09 | -$11.05M derived: sum of 2 quarters · filed 2022-11-09 | -$15.76M 10-Q · filed 2022-11-09 | -$58.64M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$3.44M 10-Q · filed 2022-11-09 | -$8.15M 10-Q · filed 2022-08-10 | -$51.03M derived: sum of 3 quarters · filed 2022-11-09 | -$55.49M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-03-31 | -$4.71M 10-Q · filed 2022-11-09 | -$47.59M derived: sum of 2 quarters · filed 2022-11-09 | -$52.05M derived: sum of 3 quarters · filed 2022-11-09 | -$55.65M derived: sum of 4 quarters · filed 2022-11-09 |
| 2020-12-31 | -$42.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$47.34M derived: sum of 2 quarters · filed 2022-03-28 | -$50.94M derived: sum of 3 quarters · filed 2022-03-28 | -$53.41M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$4.46M 10-Q · filed 2021-11-10 | -$8.06M derived: sum of 2 quarters · filed 2021-11-10 | -$10.54M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$3.60M 10-Q · filed 2021-11-10 | -$6.08M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$2.47M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |